Bio Pharma Dive
AUGUST 5, 2024
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical.
Pharmaceutical Technology
AUGUST 5, 2024
The European Commission (EC) has granted orphan drug designation (ODD) for Amylyx Pharmaceuticals’ AMX0035 to treat Wolfram syndrome.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 5, 2024
Oral diseases, such as tooth decay and gum disease, are among the the most widespread chronic illnesses globally – affecting an estimated 3.5 billion people. They pose a significant problem not just because of how common they are, but because they can cause serious health complications.
Bio Pharma Dive
AUGUST 5, 2024
All doses of the in-demand GLP-1 medicines are now available in the U.S., Lilly said ahead of reporting second quarter earnings later this week.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 5, 2024
The Drug Discovery & Development Workshop 2024 is set to be a cornerstone event for professionals and students in the pharmaceutical and biotechnology sectors. The workshop is organized by the National Institute of Animal Biotechnology (NIAB) and the Federation of Asian Biotech Associations (FABA), with the support of various institutional and knowledge partners.
Bio Pharma Dive
AUGUST 5, 2024
The decision makes Bristol the latest pharma to pull back on research into a type of cancer immunotherapy that’s drawn significant investment in recent years.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
AUGUST 5, 2024
Bowel cancer, the third most common cancer type worldwide, is the second most common cause of cancer death
Fierce Pharma
AUGUST 5, 2024
While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market. | While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market.
Worldwide Clinical Trials
AUGUST 5, 2024
Role at Worldwide: Associate Director of Project Management/Global Project Lead Joined Worldwide: September 2016 LinkedIn: Margo A Smith Get to Know Margo through this Q&A What attracted you to Worldwide and what keeps you here? What attracted me to Worldwide was its stellar reputation in the CNS research community. And it really motivated me to join Worldwide.
Pharmaceutical Technology
AUGUST 5, 2024
Reinforced with additional data, Zevra’s arimoclomol data package has gained a positive opinion in Niemann-Pick disease type C from an FDA advisory committee.
Fierce Pharma
AUGUST 5, 2024
Bristol Myers Squibb, while working its way through a major restructuring, has unveiled another round of layoffs in New Jersey. | Bristol Myers Squibb, while working its way through a major restructuring, has unveiled another round of layoffs in its home state of New Jersey.
Pharmaceutical Technology
AUGUST 5, 2024
BioNTech has given Genmab full control of their joint PD-L1 therapy program, as it recovers from Q2 losses.
Pharma Times
AUGUST 5, 2024
Head and neck cancer is currently recognised as the sixth most common cancer globally
Pharmaceutical Technology
AUGUST 5, 2024
Mallinckrodt emerged from bankruptcy in November 2023 after reducing its total funded debt by approximately $1.9bn.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
AUGUST 5, 2024
uniQure sheds two-thirds of its staff as it refocuses around a leaner pipeline headed by Huntington's therapy AMT-130
Pharmaceutical Technology
AUGUST 5, 2024
Kerendia’s Phase III study met its primary endpoint by reducing the risk of cardiovascular death and heart failure.
pharmaphorum
AUGUST 5, 2024
Learn how to effectively harmonise global content strategies with local needs in the pharmaceutical market. Understand the unique challenges in the life science industry and how to measure success with relevant KPIs.
Pharmaceutical Technology
AUGUST 5, 2024
The US FDA has accepted the BLA of SFJ Pharmaceuticals and SERB Pharmaceuticals’ bentracimab for filing and priority review.
pharmaphorum
AUGUST 5, 2024
Exploring the role of pharmacy and self-care in the fight against fatty liver and disease progression Mike.
Pharmaceutical Technology
AUGUST 5, 2024
Formosa Pharmaceuticals has signed a licensing agreement with Apotex to commercialise clobetasol propionate ophthalmic suspension.
Fierce Pharma
AUGUST 5, 2024
Bayer’s Kerendia was approved in 2021 to treat patients with chronic kidney disease (CKD) associated with Type 2 diabetes. | In a phase 3 trial, Bayer's Kerendia has shown it can reduce the risk of cardiovascular death, as well as first and recurrent heart failure events, in HF patients with mildly reduced or preserved ejection fraction.
Pharmaceutical Technology
AUGUST 5, 2024
Anivive Lifesciences has received the NIAID contract to develop a vaccine against coccidioides, the fungus responsible for valley fever.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
AUGUST 5, 2024
Discover the latest updates and insights on Agency, Consultancy, and Investor trends in the Changing Faces May-June 2024 issue featuring key players like Hanover, Real Chemistry, EVERSANA, Box Bear, and more.
Pharmaceutical Technology
AUGUST 5, 2024
Developing a robust and efficient lyophilization cycle is critical to enhancing drug product stability for sensitive drug products.
Fierce Pharma
AUGUST 5, 2024
Following a launch last summer, Krystal Biotech’s topical gene therapy Vyjuvek is continuing to make waves in the dystrophic epidermolysis bullosa (DEB) disease space. | The quarter marks a “transition point” in Vyjuvek’s launch, analysts at Evercore ISI wrote in a note to clients. While the analysts expect the drug's sales to keep growing, they cautioned of a potential slowdown in the third quarter and beyond as Krystal's initial commercial efforts shift to patient identification effo
pharmaphorum
AUGUST 5, 2024
At the start of this year, Bayer said there were two important trial readouts for the company to deliver near-term growth this year as it rebuilds its pipeline – and both have now delivered positive results in the space of a month.This morning, the German group revealed that mineralocorticoid receptor antagonist (MRA) Kerendia (finerenone) was able to reduce cardiovascular death and other heart failure events compared to placebo in the FINEARTS-HF trial.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
AUGUST 5, 2024
The pharmaceutical industry is in a constant state of evolution, driven by technological advancements, shifting consumer behaviors, and a complex regulatory landscape. | Join us at Digital Pharma East 2024 on Sept. 9-12 in Philadelphia to learn, connect, and innovate with your life sciences marketing industry peers.
BioPharma Reporter
AUGUST 5, 2024
In this Q&A, we delve into the collaboration between Skye Bioscience and Beacon Biosignals to enhance the evaluation of nimacimab, a promising treatment for obesity and its comorbid conditions, including obstructive sleep apnea (OSA).
Intouch Solutions
AUGUST 5, 2024
For the last six years, we’ve been building, evolving and perfecting our agency networks’ centralized content hub, TEDAVI. Over that time, it’s been transforming how our clients are able to achieve personalized content at scale, giving them the capacity to create, review and approve content in one place in half the time without compromising quality or creativity.
BioPharma Reporter
AUGUST 5, 2024
In this Q&A, we delve into the collaboration between Skye Bioscience and Beacon Biosignals to enhance the evaluation of nimacimab, a promising treatment for obesity and its comorbid conditions, including obstructive sleep apnea (OSA).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
264 
Let's personalize your content